Involvement of the MMR vaccine in the immune response to SARS-CoV-2 infection

Principal Investigators

Objectives

The project has four specific objectives:

  1. To determine the levels of rubella virus IgG antibodies in patients infected with SARS-CoV-2, with mild or severe disease, and in patients not infected with SARS-CoV-2.
  2. To correlate the levels of rubella virus IgG antibodies with various clinical and biochemical severity markers of COVID-19.
  3. To compare the current levels of rubella virus IgG antibodies with previous levels in those patients with available information.
  4. To compare the levels of rubella virus IgG antibodies and their evolution with the levels and evolution of the serological response to other infections with available vaccines.

Group members

  • Clàudia Fortuny

    Researcher. Pediatric Infectious Diseases Unit

  • Victoria Fumadó

    Researcher. Pediatric Infectious Diseases Unit

  • María Ríos

    Researcher. Pediatric Infectious Diseases Unit

  • Anna Gamell

    Researcher. Pediatric Infectious Diseases Unit

  • Sílvia Simó

    Researcher. Pediatric Infectious Diseases Unit

  • Eneritz Velasco-Arnaiz

    Researcher. Pediatric Infectious Diseases Unit

  • Miguel Lanaspa

    Researcher. Pediatric Infectious Diseases Unit

  • Manuel Monsonís

    Researcher. Microbiology Service

  • Pilar Subirats

    Researcher. Occupational Health Service